Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0301210 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Arun Bahadur Chand und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, KIST Medical College and Teaching Hospital, Lalitpur, Nepal. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Extensively Drug-Resistant Tuberculosis, Antitubercular Agents, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multidrug-resistant tuberculosis (MDR-TB), characterized by isoniazid and rifampicin resistance, is caused by chromosomal mutations that restrict treatment options and complicate tuberculosis management. This study sought to investigate the prevalence of pre-extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR) tuberculosis, as well as mutation pattern, in Nepalese patients with MDR/rifampicin-resistant (RR)-TB strains.
Methods
A cross-sectional study was conducted on MDR/RR-TB patients at the German Nepal Tuberculosis Project from June 2017 to June 2018. The MTBDRsl line probe assay identified pre-XDR-TB and XDR-TB. Pre-XDR-TB included MDR/RR-TB with resistance to any fluoroquinolone (FLQ), while XDR-TB included MDR/RR-TB with resistance to any FLQ and at least one additional group A drug. Mutation status was determined by comparing bands on reaction zones [ gyrA and gyrB for FLQ resistance, rrs for SILD resistance, and eis for low-level kanamycin resistance, according to the GenoType MTBDRsl VER 2.0, Hain Lifescience GmbH, Nehren, Germany definition of pre-XDR and XDR] to the evaluation sheet. SPSS version 17.0 was used for data analysis.
Results
Out of a total of 171 patients with MDR/RR-TB, 160 had (93.57%) had MTBC, of whom 57 (35.63%) had pre-XDR-TB and 10 (6.25%) had XDR-TB. Among the pre-XDR-TB strains, 56 (98.25%) were FLQ resistant, while 1 (1.75%) was SLID resistant. The most frequent mutations were found at codons MUT3C (57.14%, 32/56) and MUT1 (23.21%, 13/56) of the gyrA gene. One patient had SLID resistant genotype at the MUT1 codon of the rrs gene (100%, 1/1). XDR-TB mutation bands were mostly detected on MUT1 (30%, 3/10) of the gyrA and rrs , MUT3C (30%, 3/10) of the gyrA , and MUT1 (30%, 3/10) of the rrs .
Conclusions
Pre-XDR-TB had a significantly higher likelihood than XDR-TB, with different specific mutation bands present in gyrA and rrs genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, KIST Medical College and Teaching Hospital, Lalitpur, Nepal.
- Department of Medical Microbiology, Shi-Gan International College of Science and Technology, Kathmandu, Nepal.
- German Nepal Tuberculosis Project, Kathmandu, Nepal.
- Department of Public Health, Manmohan Memorial Institute of Health Sciences, Kathmandu, Nepal.
- Department of Dentistry, KIST Medical College and Teaching Hospital, Lalitpur, Nepal.
- Department of Microbiology, Nepal Medical College Teaching Hospital, Kathmandu, Nepal.
ORCID-Profile: Arun Bahadur Chand
Zitieren
APA
Chand, A. B., Basnet, A., Maharjan, B., Rai, G., Joshi, Y. P., Bhatt, L. R., Sen, B., & Rai, S. K. (2024). Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center. PLOS ONE. https://doi.org/10.1371/journal.pone.0301210
Vancouver
Chand AB, Basnet A, Maharjan B, Rai G, Joshi YP, Bhatt LR, et al. Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center. PLOS ONE. 2024. doi:10.1371/journal.pone.0301210
BibTeX
@article{Chand2024,
author = {Chand, Arun Bahadur and Basnet, Ajaya and Maharjan, Bhagwan and Rai, Ganesh and Joshi, Yadav Prasad and Bhatt, Lok Raj and Sen, Bindu and Rai, Shiba Kumar},
title = {Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0301210}
}
EUVIMED